MO MO Altria Group, Inc. Loading... : Bullish and Bearish Analyst Opinions

Barbarian Capital notes Philip Morris hitting a new intraday all-time high and questions whether the TAM expansion was already priced into models for PM, MO, and BTI.

Summarizes FDA guidance on vapes and pouches; no directional view from speaker.

Dr. Friedrich Franz tweets a WSJ report that Trump is pressuring the FDA to approve flavored vapes, which could benefit tobacco stocks MO and PM if approved.

Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27, 2026, but

"Zyn... is by far the biggest winner in the roughly 20 billion dollars oral tobacco market." While the video focuses on PMI's success, this implies a direct threat to competitors. Altria (MO) and British American Tobacco (BTI) have competing products (on! and Velo/Vuse), but Zyn is described as the "superior product" with dominant brand equity ("Zyn is not a sin"). If PMI is winning the growth war in oral nicotine, legacy competitors are at risk of losing the only growing segment of the industry. Watch these tickers for market share erosion. If Zyn continues to dominate the US market via the new Colorado facility, MO and BTI face an existential growth crisis. Competitors could slash prices to defend market share, triggering a margin-crushing price war.

Bondi and Rep. Fry discuss the infiltration of "illegal Chinese vapes" laced with drugs and the administration's partnership with HHS to crack down on these illicit imports. The disposable vape market has been flooded with non-compliant Chinese imports that undercut regulated players. A federal crackdown clears the market for authorized, compliant manufacturers (Big Tobacco's vape arms). Reduced illicit competition boosts pricing power and market share for established tobacco companies with FDA-authorized vapor products. Enforcement may be porous; consumers may shift to the black market rather than compliant products.